pharmaceuticals
appoints
art
taveras
chief
scientific
officer
cambridge
globe
newswire
pharmaceuticals
nasdaq
xfor
leader
discovery
development
novel
therapies
targeting
diseases
resulting
dysfunction
pathway
today
announced
appointment
art
taveras
chief
scientific
officer
taveras
lead
research
development
functions
supporting
company
pipeline
investigational
therapies
excited
welcome
taveras
chief
scientific
officer
proven
track
record
small
molecule
drug
discovery
development
significant
expertise
chemistries
support
current
clinical
programs
lead
product
candidate
mavorixafor
also
contribute
enhancement
pipeline
chemokine
receptor
antagonists
treatment
number
rare
genetic
diseases
said
paula
ragan
president
chief
executive
officer
pharmaceuticals
moreover
taveras
extensive
scientific
leadership
experience
add
great
value
continue
grow
company
broaden
pipeline
advance
ongoing
clinical
taveras
added
pleased
join
exciting
time
company
continues
progress
global
phase
trial
whim
syndrome
two
phase
trials
waldenström
macroglobulinemia
severe
congenital
neutropenia
respectively
look
forward
leveraging
expertise
experience
discovery
development
small
molecules
management
r
teams
globally
advance
mission
develop
therapeutics
change
lives
patients
rare
genetic
taveras
brings
years
experience
leading
small
molecule
research
development
programs
focused
treatment
cancer
dysregulated
immune
disorders
neurodegeneration
metabolic
diseases
research
leadership
led
development
multiple
clinical
candidates
dozens
clinical
trials
joins
comet
therapeutics
served
chief
scientific
officer
previously
founder
chief
scientific
officer
transform
therapeutics
company
aiming
discover
antagonists
treatment
cancer
served
president
chief
scientific
officer
shangpharma
chempartner
supported
discovery
initiatives
clinical
portfolios
hundreds
pharmaceutical
biotech
companies
worldwide
prior
taveras
vice
president
small
molecule
drug
discovery
cmc
development
biogen
idec
alantos
pharmaceuticals
acquired
amgen
taveras
began
career
corporation
held
multiple
roles
increasing
responsibility
oncology
immunology
drug
discovery
research
sector
period
including
leading
discovery
antagonist
currently
clinical
trials
combination
pembrolizumab
treatment
cancer
holds
issued
patents
patent
applications
authored
scientific
publications
taveras
received
rensselaer
polytechnic
institute
pharmaceuticals
pharmaceuticals
clinical
biopharmaceutical
company
leader
discovery
development
novel
therapies
treatment
diseases
resulting
dysfunction
pathway
focus
rare
diseases
limited
treatment
options
company
lead
candidate
mavorixafor
small
molecule
antagonist
chemokine
receptor
developed
oral
therapy
believes
inhibition
receptor
creates
potential
mavorixafor
provide
therapeutic
benefit
across
wide
variety
diseases
including
primary
immunodeficiencies
certain
types
cancer
efficacy
safety
mavorixafor
dosed
daily
currently
evaluated
global
phase
clinical
trial
patients
whim
syndrome
two
phase
clinical
trials
combination
ibrutinib
patients
waldenström
macroglobulinemia
monotherapy
patients
severe
congenital
neutropenia
scn
continuing
leverage
insights
biology
corporate
headquarters
cambridge
massachusetts
research
facility
vienna
austria
discovering
developing
additional
product
candidates
information
please
visit
statements
press
release
contains
statements
within
meaning
private
securities
litigation
reform
act
amended
statements
may
identified
words
may
could
would
expect
plan
anticipate
intend
believe
estimate
predict
project
potential
continue
target
similar
terms
expressions
concern
expectations
strategy
plans
intentions
statements
include
without
limitation
statements
regarding
clinical
development
mavorixafor
whim
waldenström
macroglobulinemia
indications
statements
press
release
based
management
current
expectations
beliefs
actual
events
results
may
differ
materially
expressed
implied
statements
contained
herein
including
without
limitation
risks
uncertainties
described
section
entitled
risk
factors
quarterly
report
form
filed
securities
exchange
commission
sec
august
filings
makes
sec
time
time
undertakes
obligation
update
information
contained
press
release
reflect
new
events
circumstances
except
required
law
investor
contact
dan
ferry
lifesci
advisors
daniel
media
contact
monica
rouco
molina
lifesci
communications
mroucomolina
